Bruce B. Bank
Expertise in
38
conditions

Dr. Bruce B. Bank

Oncology | Hematology
Northwest Oncology And Hematology SC
800 Biesterfield Road, Suite 210, Enter Building 5 Next To ER. Take Elevators On The Left Up To 2nd Floor., 
Elk Grove, IL 
Offers Telehealth
Referral may be required
Expertise in
38
conditions
Northwest Oncology And Hematology SC
800 Biesterfield Road, Suite 210, Enter Building 5 Next To ER. Take Elevators On The Left Up To 2nd Floor., 
Elk Grove, IL 

Overview

Bruce B. Bank, MD, is an independent medical oncologist at Ascension Illinois in Elk Grove Village near Chicago, Illinois. He diagnoses and treats cancer using medications, such as chemotherapy. Every appointment with Dr. Bank starts with a conversation. He takes the time to answer all your questions - big and small.

Dr. Bank is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Pleuropulmonary Blastoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Bone Marrow Aspiration.

Dr. Bank is board certified in American Board Of Internal Medicine, Hematology, The American Board Of Internal Medicine - Hematology, The American Board Of Internal Medicine - Medical Oncology, American Board Of Internal Medicine, Medical Hematology, American Board Of Internal Medicine; Medical Oncology, American Board Of Internal Medicine; Internal Medicine, American Board Of Internal Medicine, and The American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 18 clinical trials.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine, Hematology
The American Board Of Internal Medicine - Hematology
The American Board Of Internal Medicine - Medical Oncology
American Board Of Internal Medicine
Medical Hematology, American Board Of Internal Medicine; Medical Oncology, American Board Of Internal Medicine; Internal Medicine, American Board Of Internal Medicine
The American Board Of Internal Medicine - Internal Medicine

Fellowships

New York University School of Medicine

Hospital Affiliations

Alexian Brothers Medical Center
St Alexius Medical Center
Northwest Community Hospital
Advocate Good Shepard Hospital

Languages Spoken

English
Polish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Northwest Oncology and Hematology SC
800 Biesterfield Road, Suite 210, Enter Building 5 Next To ER. Take Elevators On The Left Up To 2nd Floor., Elk Grove, IL 60007
Other Locations
Northwest Oncology and Hematology SC
3701 Algonquin Road, Ste 900, Designated Parking Is Located On The Far West Side Of The Building. Take Elevators To 9th Floor., Rolling Meadows, IL 60008

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 9 Less Clinical Trials

4 Total Publications

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: April 06, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (21.8 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (21.9 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Altman is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Altman is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Altman is currently accepting new patients.

Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Referral may be required

Ann & Robert H. Lurie Children's Hospital Of Chicago

225 E Chicago Ave, 
Chicago, IL 
 (21.5 miles away)
312-227-4813
Languages Spoken:
English
See accepted insurances

Sherif Badawy is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Badawy is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Bruce B. Bank

How do I make an appointment with Dr. Bruce B. Bank?

You can book an appointment with Dr. Bruce B. Bank by calling their office at 847-437-3312. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bruce B. Bank a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bruce B. Bank is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bruce B. Bank specialize in?

While Dr. Bruce B. Bank is a Oncology, they have specific expertise in Multiple Myeloma, Pleuropulmonary Blastoma, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bruce B. Bank participate in research or clinical trials?

Yes. Dr. Bruce B. Bank has published 4 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Bruce B. Bank's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bruce B. Bank accept my insurance?

Dr. Bruce B. Bank accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 847-437-3312 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bank's expertise for a condition
ConditionClose
    View All 36 Advanced Conditions
    View All 118 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile